AI assistant
Sending…
MetaVia Inc. — Director's Dealing 2023
Jul 28, 2023
34919_dirs_2023-07-28_6d2e7427-0dbf-427e-baf6-906c930e5e25.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2023-07-27
Reporting Person: GROVES JASON L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-07-27 | Common Stock | A | 87500 | — | Acquired | 87500 | Direct |
| 2023-07-27 | Common Stock | A | 12500 | — | Acquired | 100000 | Direct |
Footnotes
F1: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan.
F2: 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service.
F3: Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.
More from MetaVia Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 11
Annual Report
2026
Apr 27
Proxy Solicitation & Information Statement
2026
Apr 27
Regulatory Filings
2026
Apr 10
Regulatory Filings
2026
Apr 7
Regulatory Filings
2026
Apr 3